Security key
359616109
Fulcrum Therapeutics, Inc. - Common stock, par value $0.001 per share (FULC)
CUSIP: 359616109
Q2 2020 13F Holders as of 30 Jun 2020
- Security type / class
- Equity / Common stock, par value $0.001 per share
- Total 13F shares
- 20,455,938
- Total 13F value
- $373,550,782
- Share change
- +3,628,555
- SEC-reported price per share
- $18.29
- Number of holders
- 60
- Value change
- +$66,390,720
- Number of buys
- 39
- Number of sells
- 13
- Shares outstanding
- 66,594,760
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2020
Institutions
60
Top holders
10
FULC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2020
Previous quarter: Q1 2020
Fulcrum Therapeutics, Inc. SEC filings
Fulcrum Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 359616109
Recent filing periods:
Ownership snapshot
Top reported holders of FULC - Fulcrum Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TRV GP III, LLC
Disclosed value leader
TRV GP III, LLC
Comparable rows
15/15
Latest evidence
31 Mar 2020
13F
Lead comparable stake: 9%
Showing 1-6 of 15 holder rows.
Quick read
TRV GP III, LLC leads the comparable SEC ownership view at 9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TRV GP III, LLC's linked filing trail.
Comparable ownership
Top 5
TRV GP III, LLC
9%
TRV GP IV, LLC
3.5%
FMR LLC
2.7%
Casdin Capital, LLC
1.8%
Foresite Capital Management IV, LLC
1.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TRV GP III, LLC |
13F
Company
|
9%
|
$71,189,000
5,962,202 shares
|
— | 31 Mar 2020 |
| TRV GP IV, LLC |
13F
Company
|
3.5%
|
$27,977,000
2,343,154 shares
|
— | 31 Mar 2020 |
| FMR LLC |
13F
Company
|
2.7%
|
$21,282,000
1,782,451 shares
|
— | 31 Mar 2020 |
| Casdin Capital, LLC |
13F
Company
|
1.8%
|
$14,439,000
1,209,285 shares
|
— | 31 Mar 2020 |
| Foresite Capital Management IV, LLC |
13F
Company
|
1.5%
|
$11,924,000
998,655 shares
|
— | 31 Mar 2020 |
| Alphabet Inc. |
13F
Company
|
1.1%
|
$8,670,000
726,189 shares
|
— | 31 Mar 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
60
Shares
20,455,938
Rows available
60
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2020 vs Q1 2020 Across Filers
Q1 2020 holders
46
Q2 2020 holders
60
Holder diff
14
| Investor | Q1 2020 Shares | Q2 2020 Shares | Share Diff | Share Chg % | Q1 2020 value | Q2 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend